Accordingly, it has been proposed that, in the absence of SOX2 expression, CSC self-renewal that sustains tumor growth could be abrogated,; therefore, supporting SOX2 inhibition as a potentially relevant therapeutic target for oral cancer [28]. Here, SOX2 is linked to lip and oral cavity carcinoma.